651 related articles for article (PubMed ID: 23672240)
21. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus.
Itani KM; Dryden MS; Bhattacharyya H; Kunkel MJ; Baruch AM; Weigelt JA
Am J Surg; 2010 Jun; 199(6):804-16. PubMed ID: 20227056
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of linezolid vs vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis.
Chan JD; Pham TN; Wong J; Hessel M; Cuschieri J; Neff M; Dellit TH
J Intensive Care Med; 2011; 26(6):385-91. PubMed ID: 21606058
[TBL] [Abstract][Full Text] [Related]
23. Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection.
Harbarth S; von Dach E; Pagani L; Macedo-Vinas M; Huttner B; Olearo F; Emonet S; Uçkay I
J Antimicrob Chemother; 2015 Jan; 70(1):264-72. PubMed ID: 25209610
[TBL] [Abstract][Full Text] [Related]
24. Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia.
Kelesidis T; Humphries R; Ward K; Lewinski MA; Yang OO
Diagn Microbiol Infect Dis; 2011 Nov; 71(3):286-90. PubMed ID: 21855248
[TBL] [Abstract][Full Text] [Related]
25. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.
Wunderink RG; Rello J; Cammarata SK; Croos-Dabrera RV; Kollef MH
Chest; 2003 Nov; 124(5):1789-97. PubMed ID: 14605050
[TBL] [Abstract][Full Text] [Related]
26. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis.
Wang Y; Zou Y; Xie J; Wang T; Zheng X; He H; Dong W; Xing J; Dong Y
Eur J Clin Pharmacol; 2015 Jan; 71(1):107-15. PubMed ID: 25355172
[TBL] [Abstract][Full Text] [Related]
27. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study.
Peyrani P; Wiemken TL; Kelley R; Zervos MJ; Kett DH; File TM; Stein GE; Ford KD; Scerpella EG; Welch V; Ramirez JA;
Crit Care; 2014 Jun; 18(3):R118. PubMed ID: 24916853
[TBL] [Abstract][Full Text] [Related]
28. Linezolid eradicates MRSA better than vancomycin from surgical-site infections.
Weigelt J; Kaafarani HM; Itani KM; Swanson RN
Am J Surg; 2004 Dec; 188(6):760-6. PubMed ID: 15619496
[TBL] [Abstract][Full Text] [Related]
29. Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus.
Wunderink RG; Mendelson MH; Somero MS; Fabian TC; May AK; Bhattacharyya H; Leeper KV; Solomkin JS
Chest; 2008 Dec; 134(6):1200-1207. PubMed ID: 18719064
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model.
Yin LY; Calhoun JH; Thomas TS; Wirtz ED
J Antimicrob Chemother; 2009 Feb; 63(2):357-60. PubMed ID: 19060292
[TBL] [Abstract][Full Text] [Related]
31. Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia: implications of the ZEPHyR trial.
Alaniz C; Pogue JM
Ann Pharmacother; 2012 Oct; 46(10):1432-5. PubMed ID: 22947593
[TBL] [Abstract][Full Text] [Related]
32. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
[TBL] [Abstract][Full Text] [Related]
33. Linezolid and vancomycin in treatment of lower-extremity complicated skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus in patients with and without vascular disease.
Duane TM; Weigelt JA; Puzniak LA; Huang DB
Surg Infect (Larchmt); 2012 Jun; 13(3):147-53. PubMed ID: 22568921
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
[TBL] [Abstract][Full Text] [Related]
35. [Lipopeptides and oxazolidinones--novel antibiotics in MRSA infection treatment].
Pangercić A; Bukovski-Simonoski S; Barsić B
Lijec Vjesn; 2010; 132 Suppl 1():11-3. PubMed ID: 20715711
[TBL] [Abstract][Full Text] [Related]
36. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin.
Moise PA; Forrest A; Birmingham MC; Schentag JJ
J Antimicrob Chemother; 2002 Dec; 50(6):1017-26. PubMed ID: 12461026
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
Dailey CF; Dileto-Fang CL; Buchanan LV; Oramas-Shirey MP; Batts DH; Ford CW; Gibson JK
Antimicrob Agents Chemother; 2001 Aug; 45(8):2304-8. PubMed ID: 11451689
[TBL] [Abstract][Full Text] [Related]
38. [A case of cerebral abscess due to methicillin-resistant Staphylococcus aureus which is treated with linezolid + rifampin combination].
Sipahi OR; Cağıran I; Yurtseven T; Işıkgöz Taşbakan M; Arda B; Tünger A; Ulusoy S
Mikrobiyol Bul; 2010 Oct; 44(4):651-5. PubMed ID: 21063978
[TBL] [Abstract][Full Text] [Related]
39. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid.
Chastre J; Blasi F; Masterton RG; Rello J; Torres A; Welte T
Clin Microbiol Infect; 2014 Apr; 20 Suppl 4():19-36. PubMed ID: 24580739
[TBL] [Abstract][Full Text] [Related]
40. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
